Payment overview · 2025
General Payments
$797.61
32 reported records · 9 companies
Healthcare provider profile · identity verified
Albert R Anderson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · INDIO, CA · NPI 1013002435
Verified facts
What the public records show
CMS Open Payments records show Albert R Anderson, MD received $797.61 in general payments during 2025 across 32 reported records.
AstraZeneca Pharmaceuticals LP accounted for 49.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $398.30 | 49.9% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $157.39 | 19.7% | 11 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $133.32 | 16.7% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.36 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.75 | 2.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.78 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.95 | 2.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.14 | 1.8% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $13.62 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $797.61 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $302.05 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $157.39 | 11 | 2025 |
Source payment records
|
|||||
| Intracept Normalized: intracept |
Device | Boston Scientific Corporation | $133.32 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $96.42 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $66.11 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $40.60 | 3 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.14 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 99 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
99 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
201 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1745 | 593 |
| Metformin Hcl | Metformin Hcl | 905 | 314 |
| Lisinopril | Lisinopril | 893 | 305 |
| Amlodipine Besylate | Amlodipine Besylate | 881 | 288 |
| Losartan Potassium | Losartan Potassium | 623 | 208 |
| Levothyroxine Sodium | Levothyroxine Sodium | 606 | 188 |
| Tamsulosin Hcl | Tamsulosin Hcl | 415 | 150 |
| Omeprazole | Omeprazole | 376 | 122 |
| Gabapentin | Gabapentin | 356 | 109 |
| Pantoprazole Sodium | Pantoprazole Sodium | 349 | 112 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 346 | 110 |
| Hydrochlorothiazide | Hydrochlorothiazide | 313 | 109 |
| Metoprolol Succinate | Metoprolol Succinate | 313 | 100 |
| Carvedilol | Carvedilol | 268 | 89 |
| Ibuprofen | Ibuprofen | 252 | 83 |
| Diclofenac Sodium | Diclofenac Sodium | 241 | 110 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 232 | 55 |
| Synjardy | Empagliflozin/Metformin Hcl | 218 | 64 |
| Simvastatin | Simvastatin | 214 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 205 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 205 | 61 |
| Eliquis | Apixaban | 201 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 196 | 70 |
| Benazepril Hcl | Benazepril Hcl | 182 | 56 |
| Furosemide | Furosemide | 175 | 60 |
| Trazodone Hcl | Trazodone Hcl | 168 | 52 |
| Lorazepam | Lorazepam | 164 | 46 |
| Pioglitazone Hcl | Pioglitazone Hcl | 164 | 50 |
| Alprazolam | Alprazolam | 159 | 32 |
| Finasteride | Finasteride | 159 | 48 |
| Ozempic | Semaglutide | 153 | 33 |
| Jardiance | Empagliflozin | 152 | 49 |
| Atenolol | Atenolol | 145 | 39 |
| Alendronate Sodium | Alendronate Sodium | 144 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 50 |
| Tramadol Hcl | Tramadol Hcl | 140 | 48 |
| Glipizide | Glipizide | 138 | 45 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 132 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 36 |
| Glimepiride | Glimepiride | 116 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 112 | 41 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 105 | 51 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 34 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 100 | 27 |
| Farxiga | Dapagliflozin Propanediol | 99 | 33 |
| Metformin Hcl Er | Metformin Hcl | 99 | 42 |
| Meloxicam | Meloxicam | 93 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 34 |
| Potassium Chloride | Potassium Chloride | 82 | 23 |
| Pregabalin | Pregabalin | 79 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 78 | 33 |
| Trulicity | Dulaglutide | 78 | 20 |
| Januvia | Sitagliptin Phosphate | 77 | 25 |
| Montelukast Sodium | Montelukast Sodium | 77 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 76 | 59 |
| Temazepam | Temazepam | 74 | 11 |
| Donepezil Hcl | Donepezil Hcl | 73 | 29 |
| Famotidine | Famotidine | 72 | 32 |
| Sertraline Hcl | Sertraline Hcl | 69 | 20 |
| Naproxen | Naproxen | 68 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 21 |
| Mirtazapine | Mirtazapine | 67 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 25 |
| Levetiracetam | Levetiracetam | 65 | 16 |
| Azithromycin | Azithromycin | 63 | 52 |
| Chlorthalidone | Chlorthalidone | 62 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 60 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 59 | 35 |
| Memantine Hcl | Memantine Hcl | 59 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 59 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 25 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 56 | 23 |
| Prednisone | Prednisone | 56 | 38 |
| Amoxicillin | Amoxicillin | 52 | 42 |
| Clonazepam | Clonazepam | 52 | 15 |
| Xarelto | Rivaroxaban | 52 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | 18 |
| Baclofen | Baclofen | 49 | 18 |
| Valsartan | Valsartan | 49 | 13 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 48 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 19 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 47 | suppressed |
| Lovastatin | Lovastatin | 46 | 14 |
| Nifedipine Er | Nifedipine | 45 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 17 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 33 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Tradjenta | Linagliptin | 39 | 12 |
| Methocarbamol | Methocarbamol | 38 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 36 | 19 |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | 11 |
| Azelastine Hcl | Azelastine Hcl | 32 | 16 |
| Clonidine Hcl | Clonidine Hcl | 32 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Allopurinol | Allopurinol | 29 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 29 | 11 |
| Prolia | Denosumab | 28 | 18 |
| Ketoconazole | Ketoconazole | 26 | 15 |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Estradiol | Estradiol | 24 | 12 |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 13 |
| Fluconazole | Fluconazole | 22 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 12 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | 11 |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Cimetidine | Cimetidine | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 16 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $797.61 · 32 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CeQur Simplicity, FARXIGA, GIVLAARI, Intracept, Kerendia, NURTEC ODT, OTEZLA, REPATHA, TRELEGY ELLIPTA, VOQUEZNA, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error